<DOC>
	<DOCNO>NCT00468923</DOCNO>
	<brief_summary>Heart disease stroke major cause death disability worldwide largely preventable . Cholesterol blood pressure major cardiovascular risk factor . Previous study show certain drug effectively safely low cholesterol blood pressure prevent heart attack stroke . Such study conduct primarily people already sustain heart attack stroke , people high cholesterol blood pressure level . However , heart attack stroke occur people average ( `` normal '' ) cholesterol blood pressure . Therefore , HOPE-3 trial investigator evaluate whether cholesterol lower drug , rosuvastatin , combination blood pressure lower pill , candesartan/hydrochlorothiazide , use alone together reduce risk heart attack , stroke sequelae people without know heart disease average risk .</brief_summary>
	<brief_title>Heart Outcomes Prevention Evaluation-3</brief_title>
	<detailed_description>The trial randomize 12,705 woman 60 year old men 55 year old without know heart disease prior stroke without clear indication contraindication study medication . Eligible consent individual randomize receive either active study medication placebo ( dummy pill ) monitor average 5.7 year . The rate heart attack , stroke , death cardiovascular event compare subject receive active drug placebo . The study include people 21 country , monitor international group scientist physician . The study coordinate Population Health Research Institute McMaster University . The study expect demonstrate combine lipid lower blood pressure lower substantially low risk cardiovascular disease may substantially change approach cardiovascular prevention .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Women age &gt; 60 year men &gt; 55 year At least one additional CV risk factor include : Waist/hip ratio ≥ 0.90 men ≥ 0.85 woman ; History current recent smoking ( regular tobacco use within 5 year ) Low HDL cholesterol Dysglycemia Renal dysfunction Family history premature CHD first degree relative Documented clinically manifest atherothrombotic CVD Clear indication contraindication statin and/or ARB ACE inhibitor and/or thiazide diuretic therapy Symptomatic hypotension Chronic liver disease Inflammatory muscle disease Renal impairment Concurrent treatment cyclosporine condition likely result organ transplantation need cyclosporine Concurrent treatment statin , fibrate , angiotensin receptor blocker , ACE inhibitor , thiazide diuretic Other serious medical illness likely interfere study participation ability complete trial Significant psychiatric illness , senility , dementia , alcohol substance abuse , could impair ability provide inform consent adhere trial procedure Concurrent use experimental pharmacological agent</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary prevention</keyword>
	<keyword>Cholesterol lower</keyword>
	<keyword>Blood pressure lower</keyword>
	<keyword>Cardiovascular disease prevention</keyword>
</DOC>